NAVIGATE trial: belapectin 2mg significantly reduces new varices in MASH cirrhosis patients

GALECTIN THERAPEUTICS INC

In per-protocol, belapectin 2mg reduced new varices incidence at 18 months (p=0.04) vs placebo.
Liver stiffness measure improved -12.3% mean change for belapectin 2mg vs -3.1% for placebo.
Fewer subjects on belapectin showed worsening LSM >30% or >10 kPa (p=0.03 for 2mg, p=0.02 for 4mg).
Safety profile comparable to placebo: no drug-related SAEs, no DILI, similar discontinuation rates.
U.S. subgroup showed significant varices reduction with belapectin 2mg (p=0.02).

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.